semaglutide glp 1 receptor agonist Shows Secondary Cardiovascular Prevention Benefits in Patients Without Diabetes Understanding semaglutide (GLP-1 RA): Are

In patients with CKD who are at increased risk for cardiovascular events, use of a GLP-1 RA may reduce the risk of progression of albuminuria, cardiovascular events, or both

Reinforce that approved uses come with known benefitrisk profiles based on robust trials

Signal detection based on PT levels In the Preferred Term (PT) level analysis, we implemented a rigorous screening protocol to exclude conditions that might represent therapeutic indications for GLP-1 receptor agonists and metformin combination therapy, as well as events clearly unrelated to pharmacologically-induced adverse reactions

Pharmacognosy Magazine, 21 (2), 710-716

Glycolic acid aids in removing dead skin cells, improving texture over time

Occasional reports include: Dizziness: Rare but documented